Eli Lilly Signs Up to $2.6 Billion Deal with South Korean Biotech for RNA Medicine Delivery

Eli Lilly; SanegeneBio; South Korean biotech; RNAi medicines; metabolic diseases; LEAD platform; strategic partnership; cardiometabolic; deal value; pharma news

Otsuka Acquires Asia-Pacific Rights to 4D Molecular Therapeutics’ Retinal Gene Therapy 4D-150 for $85 Million

Otsuka; 4D Molecular Therapeutics; 4D-150; Asia-Pacific rights; gene therapy; wet age-related macular degeneration; diabetic macular edema; $85 million; strategic partnership; ophthalmology

Pfizer Expands Collaboration with Flagship Pioneering, Adding Ampersand Biomedicines and Montai Therapeutics

Pfizer, Flagship Pioneering, Ampersand Biomedicines, Montai Therapeutics, strategic partnership, drug development, obesity, non-small cell lung cancer